12:08Ex Vivo Infection of Live Tissue with Oncolytic Viruses
04:46Targeting Liver Tumors with Oncolytic Viruses via the Hepatic Artery
08:55Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:51Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
06:14Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus
06:13Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Jan 20, 2026

Ex Vivo Infection of Live Tissue with Oncolytic Viruses
Published on: June 25, 2011
Christine E Engeland1, John C Bell2,3
1Research Group Mechanisms of Oncolytic Immunotherapy, Clinical Cooperation Unit Virotherapy, National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), University Hospital Heidelberg, Heidelberg, Germany. christine.engeland@nct-heidelberg.de.
Oncolytic viruses are engineered to target and destroy cancer cells, offering a promising approach for cancer immunotherapy. This review covers the principles and progress of oncolytic virotherapy in preclinical and clinical settings.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: